Nanoparticle System for High Throughput Proteomics

描述（由申请人提供）：Minerva Biotechnologies是一家纳米颗粒公司，开发了高通量蛋白质组学的专有技术。如果没有新的支持技术的发展，对每一个可能的成对交互进行顺序测试将需要大约10亿次实验。然而，假设蛋白质组中大约有4万个蛋白质，每个蛋白质可能与5个真正的结合伙伴相互作用，我们实际上只需要确定16万个相互作用对。我们认为，如果我们可以稳定地将一个蛋白质连接到编码DMA上，如果我们可以将相互作用的伙伴从非相互作用的蛋白质中分离出来，那么生成蛋白质组三维相互作用图的问题就可以解决了。正在审查的提案结合了酵母2杂交的力量和体外测试的准确性。这个提议描述了一个完整的纳米技术系统，它将使大规模并行格式的大型蛋白质相互作用网络的映射成为可能。

DESCRIPTION (provided by applicant): Minerva Biotechnologies is a nanoparticle company that has developed proprietary technology that enables high throughput proteomics. Without the development of new enabling technologies, sequential testing of every possible pair-wise interaction would require about a billion experiments. However, assuming about 40,000 proteins in the proteome and each might interact with five real binding partners, we really only need to identify 160,000 interacting pairs. We reasoned that if we could stably attach a protein to its encoding DMA, and if we could isolate interacting partners from non-interacting proteins, the problem of generating a proteome-wide 3-dimensional interaction map would be soluble. The proposal under review combines the power of yeast 2-hybrid with the accuracy of in vitro testing. This proposal describes a complete nanotechnology system that will enable the mapping of large protein interaction networks in massively parallel format.